Combination of a CpG-oligodeoxynucleotide and a topoisomerase I inhibitor in the therapy of human tumour xenografts
- 1 May 2004
- journal article
- Published by Elsevier in European Journal Of Cancer
- Vol. 40 (8) , 1275-1281
- https://doi.org/10.1016/j.ejca.2004.01.023
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Prevention of spontaneous mammary adenocarcinoma in HER‐2/neu transgenic mice by foreign DNAThe FASEB Journal, 2002
- Emerging roles of PPARS in inflammation and immunityNature Reviews Immunology, 2002
- Neutrophils are indispensable for hematopoietic stem cell mobilization induced by interleukin-8 in miceProceedings of the National Academy of Sciences, 2002
- CpG Motifs in Bacterial DNA and Their Immune EffectsAnnual Review of Immunology, 2002
- Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12European Journal of Immunology, 2001
- Interleukin-12- and Gamma Interferon-Dependent Protection against Malaria Conferred by CpG Oligodeoxynucleotide in MiceInfection and Immunity, 2001
- Signalling by CD95 and TNF receptors: Not only life and deathImmunology & Cell Biology, 1999
- Immunostimulatory DNA: Sequence‐dependent production of potentially harmful or useful cytokinesEuropean Journal of Immunology, 1997
- Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor‐α‐mediated shockEuropean Journal of Immunology, 1997
- EXPFIT: a program for simultaneous analysis of families of exponential decay curvesComputer Methods and Programs in Biomedicine, 1988